Quality of Life Analysis of Arimidex Treatment in Postmenopausal Patients With Breast Cancer
NCT ID: NCT00692289
Last Updated: 2012-06-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1510 participants
OBSERVATIONAL
2008-06-30
2010-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Survey Conducted Among Early Breast Cancer Patients Treated With Arimidex for Evaluation of Treatment Adherence
NCT01081509
Liver Safety Under Upfront Arimidex vs Tamoxifen
NCT00537771
Arimidex Observational: Reason for and Effect of Change From Tamoxifen
NCT00246961
Non-interventional Study to Evaluate Arimidex in Postmenopausal Women With Advanced Breast Cancer
NCT00562458
Effectiveness of Combination of Arimidex and Nolvadex in Adjuvant Therapy of Breast Carcinoma in Postmenopausal Women.
NCT00287534
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Postmenopausal, hormon receptor positive patients with early breast cancer treated with Arimidex
* Investigators are requested to recruit patients only with at least 1 month prior Arimidex treatment.
Exclusion Criteria
* Pre-perimenopausal woman
* Woman not eligible for treatment
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Zsolt Horváth, M.D.
Role: PRINCIPAL_INVESTIGATOR
National Institute of Oncology
Csaba Csongvai
Role: STUDY_DIRECTOR
AstraZeneca Hungary
Éva Gulyás
Role: STUDY_CHAIR
AstraZeneca Hungary
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Budapest, , Hungary
Research Site
Komló, , Hungary
Research Site
Miskolc, , Hungary
Research Site
Mohács, , Hungary
Research Site
Vác, , Hungary
Research Site
Zalaegerszeg, , Hungary
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NIS-OHU-ARI-2007/1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.